

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Organised by Leiden University  
Medical Center

Course Director Wouter Jukema, MD, PhD



Universiteit Leiden

**EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2015**

# Targeting the High-Risk Patient

## Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies

**Chaired by Christie Ballantyne**

**Sunday 30<sup>th</sup> August 2015  
12:45 – 13:45**

**Village: 2  
Room: Bratislava**

 Springer Healthcare

IME

In compliance with EBAC/ EACCME guidelines, all speakers/ Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is made possible thanks to educational sponsorship received from AstraZeneca

**AstraZeneca** 



**Targeting the High-Risk Patient**

Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies



# Contents

---

- 4**      **Programme**
  - 5**      **Chair's Welcome**
  - 6**      **Faculty Biographies**  
Christie Ballantyne
  - 7**      **Faculty Biographies**  
Alberico Catapano, Wouter Jukema, Børge Nordestgaard
  - 8**      **Symposium Information**
  - 9**      **Notes**
- 

# Programme

**Sunday 30th August 2015**  
**12:45 – 13:45**

**Village: 2**  
**Room: Bratislava**

<b>Time</b>	<b>Title</b>	<b>Speaker</b>
<b>12:45 – 12:50</b>	Welcome and opening address	Christie Ballantyne
<b>12:50 – 13:05</b>	Targeting LDL-c: commonalities and differences among major guidelines	Alberico Catapano
<b>13:05 – 13:20</b>	Triglyceride-rich lipoproteins and remnants	Børge Nordestgaard
<b>13:20 – 13:40</b>	Treatment of the high-risk patient: what do we do after statin therapy?	Wouter Jukema
<b>13:40 – 13:45</b>	Summary and close	Christie Ballantyne

## **Targeting the High-Risk Patient**

Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies



## Chair's Welcome

### Dear Colleague,

It is my pleasure on behalf of the Faculty to welcome you to this EBAC-accredited educational programme entitled *Targeting the High-Risk Patient: Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies*. We welcome you to London and hope you will enjoy this highly educational meeting.

In this symposium, Professor Alberico Catapano will discuss the commonality that all guidelines emphasise the use of a high-efficacy statin in high-risk patients to achieve greater than 50% LDL-c reduction and the controversies over targets. Professor Børge Nordestgaard will then review how the

recent genetic data have provided greater insights into triglyceride-rich lipoproteins as risk factors, not risk markers, as well as the recent trial data for triglyceride-lowering therapies. Finally, Professor Wouter Jukema will give a case presentation and review of the treatment approach for a patient with diabetes and chronic heart disease on statin therapy who still has high triglyceride levels.

We look forward to discussing these points with you during what promises to be a stimulating and informative symposium.

Best wishes,

*Christie Ballantyne*

## Faculty Biographies

### Christie Ballantyne

Dr Ballantyne is Professor of Medicine and Chief of the Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Texas. Dr Ballantyne's clinical research focuses on the prevention of atherosclerotic vascular disease. This interest includes pharmacological studies to assess the efficacy and benefits of lipid-lowering drug therapy, including trials which utilise ultrasound, MRI and other imaging modalities to examine the effects of lipid-lowering drugs on the progression of atherosclerosis. As the director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, which serves as the core laboratory for the Atherosclerosis Risk in Communities study, Dr Ballantyne is studying whether genetic variation in combination with novel biomarkers might be useful in identifying individuals at high risk for cardiovascular disease,



the metabolic syndrome and diabetes. Both genomics and proteomics are being used to identify novel molecules that are increased with atherosclerosis and the metabolic syndrome. In addition, his group is studying how genetic variation modifies the response to lipid therapy, with the goal of developing personalized diet, lifestyle and pharmacotherapy based upon the genetic profile and clinical phenotype.

### Targeting the High-Risk Patient

Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies



## Alberico Catapano

Alberico Catapano is Full Professor of Pharmacology at the University of Milano, and Director of the Laboratory for the Study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of the Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP). He holds board positions in several learned Scientific Societies, including the Italian Society for the Study of Atherosclerosis; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation. He has authored more than 300 scientific papers in peer-reviewed journals and several books in the area of the atherosclerosis, lipoproteins and lipid metabolism, and is on the Editorial Boards of several leading journals in this field.



## Wouter Jukema

J. Wouter Jukema, MD, PhD, FESC, FACC, is Professor of Cardiology and Chairman of “Leiden Vascular Medicine” at Leiden University Medical Center (LUMC) in the Netherlands. Furthermore, he is Co-Chairman of the Dutch Atherosclerosis Society as well as past “established clinical investigator” of the Netherlands Heart Foundation”. His research focuses on the field of athero-thrombosis and includes atherosclerosis research as well as interventional cardiology (vascular biology, lipid modification, diabetes, anti-thrombotics/anti-platelets and genetics research) in both humans and transgenic animals. He has a large number of peer-reviewed publications (with many in top journals such as the New England Journal of Medicine, Lancet, Nature Genetics, Nature Reviews, Jama, Circulation, JACC and EHJ). Professor Jukema is principal investigator in several large athero-thrombosis studies, a member of various national and international athero-thrombosis boards and holder of multiple major (inter) national, a.o. European Union, grants.



## Børge Nordestgaard

Dr Nordestgaard is Chief Physician in Clinical Biochemistry at Copenhagen University Hospital and Professor in Genetic Epidemiology at the University of Copenhagen, Denmark. He is Chair of the Copenhagen General Population Study, a biobank and research study involving at least 100,000 volunteers from the Copenhagen area. Research based on the Copenhagen General Population Study has focused on genetic epidemiology, as well as investigation of the association of other variables such as lipoprotein(a) and triglycerides with risk of cardiovascular disease. He is also a Steering Committee member of the Copenhagen City Heart Study, the LIFE Genetic Sub-study, the JUPITER trial, and the High Risk Plaque Initiative.

# Symposium Information

## Organisers

This educational activity has been planned and independently implemented by Springer Healthcare IME.

Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Science+Business Media global publishing group.

## CME

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Certificates will be emailed to attendees following the event.

## Educational Sponsorship

This programme is made possible thanks to educational sponsorship received from AstraZeneca.



## Filming and Photography

Springer Healthcare may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team your objection to this, your consent will be implied.

### Targeting the High-Risk Patient

Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies










**Targeting the High-Risk Patient**

Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies



A series of 18 horizontal blue lines for writing, arranged in a central column.





Springer Healthcare

IME